UY37003A - Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion - Google Patents

Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion

Info

Publication number
UY37003A
UY37003A UY0001037003A UY37003A UY37003A UY 37003 A UY37003 A UY 37003A UY 0001037003 A UY0001037003 A UY 0001037003A UY 37003 A UY37003 A UY 37003A UY 37003 A UY37003 A UY 37003A
Authority
UY
Uruguay
Prior art keywords
compositions
methods
cytoquine
immunor
regulation
Prior art date
Application number
UY0001037003A
Other languages
English (en)
Inventor
Michael Didonato
Shelly Meeusen
Glen Spraggon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57543103&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37003A publication Critical patent/UY37003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Esta descripción proporciona composiciones de anticuerpo injertadas con citoquina, incluyendo, por ejemplo, constructos injertados que se unen a y estimulan la señalización intracelular por un miembro de la super-familia del receptor de interleucina, y estimulan la señalización. Composiciones proporcionadas encuentran uso en mejora de respuestas de células anti-inflamatorias, y relativamente reducen efectos pro-inflamatorios en el tratamiento, mejora, prevención de trastornos relacionados con el sistema inmune que pueden ser contrarrestados con una respuesta anti-inflamatoria aumentada. Se proporcionan polinucleótidos y vectores que codifican tales moléculas y células huésped capaces de producir moléculas, así como también métodos de fabricación y uso de composiciones.
UY0001037003A 2015-12-04 2016-12-01 Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion UY37003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263008P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
UY37003A true UY37003A (es) 2017-06-30

Family

ID=57543103

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037003A UY37003A (es) 2015-12-04 2016-12-01 Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion

Country Status (25)

Country Link
US (3) US10144768B2 (es)
EP (1) EP3383891A1 (es)
JP (2) JP6794448B2 (es)
KR (2) KR20210016479A (es)
CN (1) CN108602870A (es)
AR (1) AR106908A1 (es)
AU (1) AU2016362777B2 (es)
BR (1) BR112018010937A2 (es)
CA (1) CA3006477A1 (es)
CL (1) CL2018001427A1 (es)
CO (1) CO2018005678A2 (es)
CU (1) CU20180047A7 (es)
EA (1) EA201891341A1 (es)
EC (1) ECSP18041733A (es)
IL (1) IL259529A (es)
MA (1) MA43372A (es)
MX (1) MX2018006778A (es)
PE (1) PE20181358A1 (es)
PH (1) PH12018501160A1 (es)
RU (1) RU2018124307A (es)
SA (1) SA518391711B1 (es)
SG (1) SG11201804259UA (es)
TW (1) TW201726716A (es)
UY (1) UY37003A (es)
WO (1) WO2017093947A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018215937A1 (en) * 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
AU2018274216A1 (en) * 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JP2020520671A (ja) * 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び使用方法
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
EP3934681A4 (en) * 2019-03-06 2023-12-20 Deka Biosciences, Inc. IL-10 VARIANT MOLECULES AND METHODS OF TREATMENT OF INFLAMMATORY DISEASE AND ONCOLOGY
MX2021015301A (es) * 2019-06-10 2022-02-03 Takeda Pharmaceuticals Co Métodos de cultivo celular y composiciones para la producción de anticuerpos.
US20220267396A1 (en) * 2019-07-08 2022-08-25 Progen Co., Ltd. Novel il-10 variant protein and use thereof
CN110472294B (zh) * 2019-07-19 2022-09-30 河南科技大学 一种嫁接涡旋光束的掩模板的设计方法
CN116615462A (zh) 2020-11-23 2023-08-18 诺华股份有限公司 抗体构建体的表达技术
EP4330383A1 (en) 2021-04-29 2024-03-06 Novartis AG Hypersialylating cells
TW202325746A (zh) * 2021-11-02 2023-07-01 大陸商廣東菲鵬製藥股份有限公司 中國廣東省東莞市松山湖園區桃園路1號10棟301室 郵編：523808 Il10單體融合蛋白及其應用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0517895B1 (en) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
CA2320403A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2380367T3 (es) * 2000-12-05 2012-05-11 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
WO2003086286A2 (en) 2002-04-09 2003-10-23 The Curators Of The University Of Missouri Treatment of type 1 diabetes before and after expression of predisposition markers
JP4421900B2 (ja) * 2002-04-09 2010-02-24 ザ スクリップス リサーチ インスティテュート モチーフ・グラフトされたハイブリッドポリペプチドおよびその使用
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2004108078A2 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
CA2553692C (en) 2004-01-20 2014-10-07 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
PT2343380T (pt) 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
EP2769991B1 (en) 2008-01-03 2018-08-22 The Scripps Research Institute Antibody targeting through a modular recognition domain
EP2752427A1 (en) * 2009-02-24 2014-07-09 Alexion Pharmaceuticals, Inc. Antibodies containing therapeutic TPO/EPO mimetic peptides
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
NZ600899A (en) 2009-11-30 2014-09-26 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012045334A1 (en) * 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
CA2824252A1 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Improved immunotherapy
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
CN104662045B (zh) 2012-08-07 2019-04-05 罗切格利卡特公司 包含两种工程化改造成具有降低的和升高的效应器功能的抗体的组合物改进的免疫疗法
KR20150038012A (ko) 2012-08-08 2015-04-08 로슈 글리카트 아게 인터루킨-10 융합 단백질 및 그의 용도
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
US11338036B2 (en) * 2013-03-08 2022-05-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
PT3019533T (pt) 2013-07-11 2020-04-17 Scripps Research Inst Proteínas de fusão de imunoglobulinas de hélices super-enroladas e composições das mesmas
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
SI3102595T1 (sl) 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão

Also Published As

Publication number Publication date
EA201891341A1 (ru) 2018-11-30
EP3383891A1 (en) 2018-10-10
CO2018005678A2 (es) 2018-06-12
MA43372A (fr) 2018-10-10
US20190241636A1 (en) 2019-08-08
KR102213790B1 (ko) 2021-02-09
IL259529A (en) 2018-07-31
WO2017093947A1 (en) 2017-06-08
RU2018124307A (ru) 2020-01-14
US20220127321A1 (en) 2022-04-28
AU2016362777B2 (en) 2020-01-30
AR106908A1 (es) 2018-02-28
BR112018010937A2 (pt) 2018-12-04
TW201726716A (zh) 2017-08-01
RU2018124307A3 (es) 2020-05-13
JP2019505173A (ja) 2019-02-28
PE20181358A1 (es) 2018-08-22
KR20210016479A (ko) 2021-02-15
US10144768B2 (en) 2018-12-04
US11136366B2 (en) 2021-10-05
ECSP18041733A (es) 2018-06-30
JP6794448B2 (ja) 2020-12-02
MX2018006778A (es) 2018-08-01
CU20180047A7 (es) 2018-07-05
KR20180081622A (ko) 2018-07-16
US20170158747A1 (en) 2017-06-08
PH12018501160A1 (en) 2019-01-21
CN108602870A (zh) 2018-09-28
SA518391711B1 (ar) 2021-07-27
CA3006477A1 (en) 2017-06-08
JP2021040637A (ja) 2021-03-18
CL2018001427A1 (es) 2018-07-27
AU2016362777A1 (en) 2018-06-07
SG11201804259UA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
UY37003A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
ECSP17005276A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
UY36154A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
AR099289A1 (es) Proteínas de fusión de interleucina-2 y usos de las mismas
NZ761188A (en) Antibody molecules to tim-3 and uses thereof
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
UY37738A (es) Proteínas injertadas de anticuerpo-citoquina y métodos de uso para trastornos inmunes relacionados
CL2018000103A1 (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
CL2016002088A1 (es) Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica.
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
DOP2018000019A (es) Inmunoconjugados de il22
UY37281A (es) Variantes de gm-csf y métodos de uso
AR105945A1 (es) Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer
AR101592A1 (es) Tratamiento de cáncer usando un receptor quimérico de antígeno cd123
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
CL2012001309A1 (es) Anticuerpos humanizados contra el receptor alfa de la interleucina 22 (il-22ra) humana; polinucleotido que codifica tanto la cadena pesada como la cadena liviana de dicho anticuerpo; vector y celula hospedera que comprende dicho polinucleotido; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar soriasis, artritis soriatica o dermatitis atópica.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221212